Neurocrine Biosciences (NBIX) Misses Q1 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Neurocrine Bio. (NBIX) PT Raised to $99 at Deutsche Bank
May 1, 2018 7:40 AM EDTDeutsche Bank raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $99.00 (from $97.00) while maintaining a Buy rating.
Analyst Andrew Peters commented, "Another solid quarter of commercial execution and continued pipeline advancement confirm our bullish outlook on Neurocrine, with continued success of the Ingrezza launch and further revenue... More
Neurocrine Bio. (NBIX) PT Raised to $100 at Baird After Another Beat for Ingrezza
May 1, 2018 7:15 AM EDTBaird raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $100.00 (from $84.00) while maintaining an Outperform rating following another strong quarter for Ingrezza.
Analyst Brian Skorney commented, "Investor fears about a quarter of declining sequential growth turned out to be unfounded as... More
